The etiology of cholangiocarcinoma is still unknown, and the prognosis is extremely poor. The average survival time for surgical resection is 13 months, and rarely survives for 5 years. Progressive obstructive jaundice is the main symptom of cholangiocarcinoma, often accompanied by pruritus. Patients may have distension and pain in the upper and middle abdomen, loss of appetite, weight loss and fever, but the degree of fever is generally mild. The liver is often enlarged and may show portal hypertension in the subcostal or subxiphoid crumbs. According to the location of the cancer, it can be divided into upper segment, middle segment and lower segment. The upper segment includes the left and right hepatic ducts and the common hepatic duct, and more cancers occur here, accounting for 40% to 75% of bile duct cancers; the middle segment refers to the section of the common bile duct located from the cystic duct to above the lower edge of the common bile duct; the lower segment refers to the bile duct located between the lower edge of the common bile duct and the jugular of Sparte. There are 3 types of carcinomas according to the naked eye: 1. papillary type: often multiple, mostly found in the lower bile duct. 2. 2.Nodular type: generally small and limited masses, mostly seen in the middle bile ducts. 3.Diffuse type: Mostly, it shows obvious thickening of the duct wall in a wide area with luminal narrowing. Adenocarcinoma is the most common type of bile duct cancer, while squamous cell carcinoma and sarcoma are very rare. Adenocarcinoma can be divided into papillary adenocarcinoma, mucinous adenocarcinoma and sclerosing adenocarcinoma. The size of bile duct cancer is usually small, but it often infiltrates the entire bile duct wall or protrudes into the lumen early, forming a circumferential stricture that leads to bile duct obstruction and jaundice, bleeding and infection symptoms. Most cholangiocarcinomas are confined to the primary site, while hilar cancer often spreads to the opposite side or common hepatic duct. Cholangiocarcinoma often infiltrates the liver and local lymph nodes earlier, followed by gallbladder, peritoneal surface, plasma membrane surface of gastrointestinal tract and periaortic lymph nodes. The pancreas, bladder and rectal recesses are the next. Clinically, most patients diagnosed with cholangiocarcinoma are already in the middle and late stages, and the effect of surgical resection is poor, and they are not sensitive to radiotherapy. We have performed ERCP and internal drainage (metal stent release) for patients with bile duct cancer and supplemented with Chinese herbal medicine to support and suppress cancer, which has achieved more obvious clinical results, greatly improved the quality of life and prolonged the survival of patients with bile duct cancer, and is a more ideal method and choice for the treatment of bile duct cancer at present.